Close to 130 industry and non-industry players, across the globe, claim to have the necessary expertise. <Roots Analysis> Knowpia

The production of radiopharmaceuticals as compared to traditional pharmaceuticals is a multifaceted procedure and requires specialized facilities, equipment and operational expertise. Further, owing to its inherent hazardous nature, radiopharmaceuticals have a complex regulatory market authorization process. Consequently, a number of innovator companies have demonstrated a preference for outsourcing radiopharmaceutical manufacturing to contract service providers.

To order this 320+ page report, which features 45+ figures and 100+ tables, please visit this - https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

The USD 6+ billion (by 2030) financial opportunity associated with nuclear medicine and radiopharmaceuticals manufacturing, has been analyzed across the following segments:

§ Target Disease Indication

Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Lupus Nephritis
Melanoma
Multiple Myeloma
Primary Sjögren's Syndrome
Others

§ Target Immune Checkpoint

B7-H3
CD38
CD40
CD47
Others

§ Mechanism of Action

Inhibitory
Stimulatory

§ Therapeutic Modality

Monoclonal Antibody
Small Molecule

§ Type of Therapy

Monotherapy
Combination Therapy

§ Route of Administration

Intravenous
Subcutaneous
Others

§ Key Geographical Regions

North America
Europe
Asia-Pacific and the Rest of the World

The Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:

§ Advanced Accelerator Applications

§ Belgian Nuclear Research Center (SCK•CEN)

§ Cardinal Health

§ China Isotope & Radiation Corporation

§ Curium Pharma

§ DuChemBio

§ Eckert & Ziegler

§ Eczacibasi-Monrol

§ GE Healthcare

§ Jubilant DraxImage

§ Lantheus Medical Imaging

§ Nihon Medi-Physics